STOP GAMES Act of 2026
Sponsored By: Representative Sorensen, Eric [D-IL-17]
Introduced
Summary
Stop delay-by-petition tactics to speed drug approvals. This bill would tighten when and how citizen petitions can be filed, let FDA deny petitions submitted primarily to delay review, and add new reporting and judicial limits to shorten review timelines.
Show full summary
- Drug applicants would face fewer last-minute obstacles. FDA would have to move toward a final decision after 151 days from petition submission, shrinking the window for petitions to block approval.
- Petitioners and public interest groups would need to act faster and meet stricter rules. Petitions must be in writing and filed within 60 days of when the supporting information became known. FDA could deny petitions that lack data or are plainly meant to delay and could refer suspected delay tactics to the Federal Trade Commission.
- Courts and challengers would see tighter limits on lawsuits. Plaintiffs must first file a petition to exhaust remedies, and suits filed after the 151-day window or that seek to delay approval can be dismissed under new standards.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
New limits on FDA citizen petitions
This bill would let the FDA deny any citizen petition or supplement the agency finds was filed mainly to delay approval or that on its face lacks valid scientific or regulatory issues. The bill would require petitions to be in writing under FDA rules and certified no later than 60 days after the filer first learned the underlying information. It would create a 151-day administrative benchmark after petition filing; after that point certain lawsuits must be dismissed and the related application is treated as having been approved for timing purposes. The bill would require FDA to report each petition’s filer, the time and resources spent, and an estimate of how much each petition delayed approval, and would require the FDA to refer delay-motivated petitions to the FTC.
Sponsors & CoSponsors
Sponsor
Sorensen, Eric [D-IL-17]
IL • D
Cosponsors
Rep. Bice, Stephanie I. [R-OK-5]
OK • R
Sponsored 5/19/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov